Skandinaviska Enskilda Banken AB publ Sells 394,017 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Skandinaviska Enskilda Banken AB publ cut its stake in Sana Biotechnology, Inc. (NASDAQ:SANA) by 67.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 189,472 shares of the company’s stock after selling 394,017 shares during the period. Skandinaviska Enskilda Banken AB publ owned about 0.08% of Sana Biotechnology worth $305,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its stake in Sana Biotechnology by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company’s stock worth $1,722,000 after acquiring an additional 8,666 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Sana Biotechnology by 3.0% in the fourth quarter. Bank of New York Mellon Corp now owns 336,828 shares of the company’s stock valued at $549,000 after purchasing an additional 9,905 shares during the period. Ieq Capital LLC bought a new position in Sana Biotechnology in the fourth quarter worth approximately $32,000. Blue Trust Inc. increased its holdings in Sana Biotechnology by 203.4% during the 4th quarter. Blue Trust Inc. now owns 39,827 shares of the company’s stock worth $65,000 after purchasing an additional 26,698 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in Sana Biotechnology by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,341 shares of the company’s stock valued at $77,000 after purchasing an additional 4,554 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

Shares of Sana Biotechnology stock opened at $2.77 on Tuesday. Sana Biotechnology, Inc. has a one year low of $1.52 and a one year high of $10.50. The company has a market capitalization of $618.46 million, a PE ratio of -1.98 and a beta of 1.63. The company has a 50-day simple moving average of $3.05 and a two-hundred day simple moving average of $3.23.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Thursday, March 20th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). On average, equities analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 31.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on SANA shares. HC Wainwright raised their price target on Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, Jefferies Financial Group initiated coverage on shares of Sana Biotechnology in a research note on Friday. They set a “buy” rating and a $7.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.